Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference takes place June 15-16, 2026, with the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT.
The presentation is significant as it provides a platform for Helus Pharma to discuss its pipeline of proprietary NSAs, which target serotonin pathways to promote neuroplasticity. The company is currently advancing HLP003, a Phase 3 NSA for major depressive disorder (MDD) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another NSA, is in Phase 2 development for generalized anxiety disorder (GAD). These programs address large unmet needs in mental health, where current treatments often have limited efficacy or significant side effects.
Amir Inamdar's participation highlights the company's focus on clinical development and regulatory strategy. The H.C. Wainwright conference is a key event for investors and industry stakeholders to gain insights into emerging neuropsychiatric therapies. Helus Pharma's approach with NSAs aims to provide durable improvements in mental health, potentially differentiating it from existing antidepressants and anxiolytics.
For more details on the announcement, visit the full press release here. Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company continues to expand its research portfolio of investigational NSAs. Further information is available at www.helus.com.
The conference participation underscores Helus Pharma's commitment to advancing its pipeline and engaging with the investment community. With Phase 3 data for HLP003 expected, the company is positioned to potentially reshape the treatment landscape for MDD and GAD.
